Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Outlook Therapeutics (OTLK) EBIT (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed EBIT for 8 consecutive years, with -$13.5 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 37.59% to -$13.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$58.9 million through Dec 2025, down 21.69% year-over-year, with the annual reading at -$67.1 million for FY2025, 6.47% up from the prior year.
  • EBIT for Q4 2025 was -$13.5 million at Outlook Therapeutics, up from -$17.3 million in the prior quarter.
  • The five-year high for EBIT was -$12.4 million in Q1 2025, with the low at -$21.6 million in Q4 2024.